Physician profile
Ramin Sam
NPI 1790794873
$16,677.45
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,315 · 2022: $4,412 · 2023: $3,380 · 2024: $4,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,300 · Travel and Lodging: $1,210 · Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,300.00 |
| Travel and Lodging | $1,210.32 |
| Food and Beverage | $440.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $4,391.85 | 2022 | |
| Fresenius USA Marketing, INC. | $4,335.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $3,379.89 | 2023 | |
| Calliditas Therapeutics US INC. | $3,000.00 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $1,369.26 | 2024 | |
| Amgen INC. | $111.15 | 2024 | Tavneos |
| Vertex Pharmaceuticals Incorporated | $90.23 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.